IP Library Granted Patent US 8,568,777
Granted Patent B2
US 8,568,777 · App. 11/731,139 · Granted Oct 29, 2013

Packaged film dosage unit containing a complexate

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,568,777
App. No.
11/731,139
Granted
Oct 29, 2013
Kind
B2
Abstract

The present invention relates to packaged orally consumable film dosage units for delivery of actives into the oral cavity. In particular, the packaged pharmaceutical product contains a complexate including a complexing agent and an active, an orally consumable film for delivery of the complexate and a package for containing the orally consumable film. The package includes indicia associated therewith. The indicia identifies the complexate as the active ingredient contained in the film, which is as a regulatory approvable chemical entity. The present invention also relates to methods of labeling, pricing, marketing and satisfying governmental regulations for such packaged pharmaceutical products.

Claims (35)

1. A packaged pharmaceutical product comprising:

a taste-masked complexate comprising a complexing agent comprising an ion exchange resin and an active, wherein said ion exchange resin controls the release of said active and improves the stability of said active and wherein said complexate is a distinct chemical entity when compared to said active;

an orally consumable film comprising said complexate, wherein the orally consumable film has mucoadhesive properties and a minimum dissolution time of at least a few minutes; and

a package for containing said orally consumable film, said package comprising indicia associated therewith identifying said complexate as a regulatory approvable chemical entity.

2. The pharmaceutical product of claim 1 , wherein said active comprises a charged active.

3. The pharmaceutical product of claim 1 , wherein said complexing agent comprises an anionic complexing agent.

4. The pharmaceutical product of claim 1 , wherein said complexing agent comprises a cationic complexing agent.

5. The pharmaceutical product of claim 2 , wherein said charged active comprises an anionic active.

6. The pharmaceutical product of claim 2 , wherein said charged active comprises a cationic active.

7. The pharmaceutical product of claim 1 , wherein said complexing agent comprises a multi-valent salt.

8. The pharmaceutical product of claim 1 , wherein said complexing agent comprises a zeolite.

9. The pharmaceutical product of claim 1 , wherein said complexing agent comprises a caged molecule.

10. The pharmaceutical product of claim 9 , wherein said caged molecule comprises a cyclodextrin.

11. The pharmaceutical product of claim 1 , wherein said package comprises a pouch.

12. The pharmaceutical product of claim 1 , wherein said package comprises a box.

13. The pharmaceutical product of claim 1 , wherein said package comprises a cassette.

14. The pharmaceutical product of claim 1 , wherein said indicia comprises a label.

15. The pharmaceutical product of claim 14 , wherein said label is located on said package.

16. The pharmaceutical product of claim 14 , wherein said label is affixed to said package.

17. The pharmaceutical product of claim 1 , wherein said indicia comprises a list of active ingredients.

18. The pharmaceutical product of claim 1 , wherein said indicia identifies said complexate as an active ingredient.

19. A method of labeling a packaged pharmaceutical product in a manner that is consistent with governmental drug regulations, comprising the steps of:

(a) providing a packaged pharmaceutical product comprising:

(i) a taste-masked complexate comprising a complexing agent comprising an ion exchange resin and a pharmaceutical active, wherein said ion exchange resin controls the release of said active and improves the stability of said active and wherein said complexate is a distinct chemical entity when compared to said active;

(ii) an orally consumable film comprising said complexate, wherein said orally consumable film has mucoadhesive properties and a minimum dissolution time of at least a few minutes; and

(iii) a package for containing said orally consumable film;

(b) adding indicia to said package, said indicia comprising a list of active ingredients contained in said orally consumable film and a list of inactive ingredients contained in said orally consumable film, wherein said complexate is listed as an active ingredient.

20. The method of claim 19 , wherein said indicia added to said package in step (b) identifies said complexate as a regulatory approvable chemical entity.

21. A method of disseminating accurate drug information to consumers of a packaged pharmaceutical product, comprising the steps of:

(a) providing a packaged pharmaceutical product comprising:

(i) a taste-masked complexate comprising a complexing agent comprising an ion exchange resin and a pharmaceutical active wherein said ion exchange resin controls the release of said active and improves the stability of said active and wherein said complexate is a distinct chemical entity when compared to said active;

(ii) an orally consumable film comprising said complexate, wherein said orally consumable film has mucoadhesive properties and a minimum dissolution time of at least a few minutes; and

(iii) a package for containing said orally consumable film;

(b) providing indicia identifying the complexate as an active ingredient contained in the packaged pharmaceutical product; and

(c) exposing consumers to the indicia, thereby providing accurate information as to the active ingredient contained in the packaged pharmaceutical product.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded May 13, 2026
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: AQUESTIVE THERAPEUTICS, INC.
Reel/Frame 075646/0258 →
SECURITY INTEREST Recorded May 12, 2026
From: AQUESTIVE THERAPEUTICS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 075561/0782 →
SECURITY INTEREST Recorded Nov 2, 2023
From: AQUESTIVE THERAPEUTICS, INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 065446/0494 →
RELEASE OF SECURITY INTEREST Recorded Nov 1, 2023
From: U.S. BANK TRUST COMPANY NATIONAL ASSOCIATION (AS SUCCESSOR IN INTEREST TO U.S BANK NATIONAL ASSOCIATION)
To: AQUESTIVE THERAPEUTICS, INC.
Reel/Frame 065426/0642 →
RELEASE OF SECURITY INTEREST Recorded Jul 15, 2019
From: PERCEPTIVE CREDIT HOLDINGS, LP
To: AQUESTIVE THERAPEUTICS, INC.; MONOSOL RX, INC.; MSRX US, LLC
Reel/Frame 049757/0733 →
SECURITY INTEREST Recorded Jul 15, 2019
From: AQUESTIVE THERAPEUTICS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 049758/0082 →
AMENDMENT TO PATENT SECURITY AGREEMENT RECORDED AT REEL/FRAME 039707/0194 Recorded Jan 30, 2018
From: AQUESTIVE THERAPEUTICS, INC.
To: PERCEPTIVE CREDIT HOLDINGS, LP
Reel/Frame 045279/0802 →
CHANGE OF NAME Recorded Jan 29, 2018
From: MONOSOL RX, LLC
To: AQUESTIVE THERAPEUTICS, INC.
Reel/Frame 045196/0389 →
RELEASE OF SECURITY INTEREST Recorded Aug 22, 2016
From: WHITE OAK GLOBAL ADVISORS, LLC
To: MONOSOL RX, LLC
Reel/Frame 039774/0782 →
SECURITY INTEREST Recorded Aug 16, 2016
From: MONOSOL RX, LLC; MONOSOL RX, INC.; MSRX US, LLC
To: PERCEPTIVE CREDIT HOLDINGS, LP
Reel/Frame 039707/0194 →
SECURITY AGREEMENT Recorded Dec 18, 2012
From: MONOSOL RX, LLC
To: WHITE OAK GLOBAL ADVISORS, LLC, AS AGENT
Reel/Frame 029490/0156 →